Log in to save to my catalogue

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymp...

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymp...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0549dc4da85f4345b069b254b508c05d

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

About this item

Full title

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

Publisher

England: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002303

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundChimeric antigen receptor T-cell (CAR-T) infusion is associated with early toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is unknown.MethodsFrom a large cohort of consecutive adult patients treated with CAR-T therapies for relapsed or refractory lymphomas from 2016 to 2019, we assessed progres...

Alternative Titles

Full title

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_0549dc4da85f4345b069b254b508c05d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0549dc4da85f4345b069b254b508c05d

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-002303

How to access this item